SunTrust analyst Edward Nash raised his price target on RA Pharmaceuticals to $35 and kept his Buy rating after its positive top-line results from a Phase II zilucoplan trial that are “comparable, if not better, to Soliris’ Phase III REGAIN data.” The analyst notes that the patients in the trial “did not require rescue therapy” and that the drug’s safety profile was “mild”. Nash believes that “zilucoplan is well positioned to treat broader generalized myasthenia gravis, or gMG, patients than Soliris, given its subQ delivery and a more accessible pricing.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.